Actively Recruiting
Physiological Effects of ANGPTL3 Variants in Humans
Led by University of Pennsylvania · Updated on 2025-09-10
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Pennsylvania
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating how genetic variants of ANGPTL3 affect lipid and glucose metabolism in humans. The study aims to understand the role of this protein in these metabolic processes through detailed testing. This research involves volunteers with and without ANGPTL3 variants and includes healthy individuals as controls. Participants will undergo a series of tests including an oral fat tolerance test, lipoprotein kinetics test, and an oral glucose tolerance test. These procedures are designed to assess how ANGPTL3 variants influence lipid and glucose metabolism over the course of the study, which lasts an average of 13 weeks. During the study, participants will be monitored through these metabolic tests to measure outcomes related to lipid metabolism, glucose metabolism, and fatty acids. The research team will collect data throughout the study period to evaluate the effects of ANGPTL3 variants. Participants are expected to follow the study procedures and provide informed consent prior to participation.
CONDITIONS
Brief Title
Physiological Effects of ANGPTL3 Variants in Humans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects aged 18 or older
- Carrying genetic variants in the gene encoding for ANGPTL3, or unaffected controls matched for age, race, and gender
- Willing to follow study procedures
- Able to provide informed consent
You will not qualify if you...
- Any medical or psychological condition that may compromise safety or study participation
- Taking medications that may affect safety or study data
- Women who are pregnant or nursing
- History of liver disease or abnormal liver function tests above twice the upper limit
- History of kidney disease or chronic renal insufficiency (eGFR below 60 mL/min/1.73 m2)
- Uncontrolled hypertension (above 160/100 mmHg)
- Uncontrolled diabetes
- Anemia with hemoglobin below 11.0 mg/dL
- History of non-skin cancer within the past 5 years
- Major surgery within the past 3 months
- History of any organ transplant
- History of alcohol or drug abuse
- Participation in clinical trials affecting lipid metabolism within the past 6 weeks or longer
- Inability to comply with study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 day
Participants undergo a kinetics test, oral fat tolerance test, and an oral glucose tolerance test to evaluate lipid and glucose metabolism related to ANGPTL3 variants.
1 visit (in-person)
Duration - Approximately 13 weeks
Participants are monitored over approximately 13 weeks to assess the role of ANGPTL3 on lipid, glucose, and fatty acid metabolism.
Periodic visits over 13 weeks
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
M
Marina Cuchel, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here